BioTuesdays

Tag - Maxim Group

Cingulate Logo

Maxim starts Cingulate at buy; PT $3

Maxim Group launched coverage of Cingulate (NASDAQ:CING) with a “buy” rating and price target of $3. The stock closed at 69 cents on Nov. 21. Cingulate is a Phase 3-ready company developing multiple therapies for...

Fennec Pharmaceuticals Logo

Maxim ups Fennec PT to $15 on PEDMARK approval

Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of...

BioRestorative Therapies Logo

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

Aridis Pharmaceuticals Logo

Maxim cuts Aridis Pharma to hold

Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...

scPharmaceuticals Logo

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

Medivir AB Logo

Maxim starts Medivir at buy; PT $3

Maxim Group initiated coverage of Sweden-based Medivir AB (OMX:MVIR-B) with a “buy” rating and $3 price target. The stock closed at 77 cents on June 16. Medivir is developing MIV-818 (fostrox), a prodrug of the...

Maxim starts Femasys at buy; PT $5

Maxim Group launched coverage of Femasys (NASDAQ:FEMY) with a “buy” rating and $5 price target. The stock closed at $1.30 on June 16. Femasys is developing treatments to address the two extremes of the women’s...